You are here » Home » Companies » Company Overview » Aarti Drugs Ltd

Aarti Drugs Ltd.

BSE: 524348 Sector: Health care
NSE: AARTIDRUGS ISIN Code: INE767A01016
BSE 00:00 | 14 May 817.85 20.65
(2.59%)
OPEN

800.00

HIGH

841.40

LOW

795.85

NSE 00:00 | 14 May 817.50 19.20
(2.41%)
OPEN

804.00

HIGH

841.80

LOW

796.10

OPEN 800.00
PREVIOUS CLOSE 797.20
VOLUME 100852
52-Week high 1025.00
52-Week low 187.50
P/E 29.56
Mkt Cap.(Rs cr) 7,622
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 800.00
CLOSE 797.20
VOLUME 100852
52-Week high 1025.00
52-Week low 187.50
P/E 29.56
Mkt Cap.(Rs cr) 7,622
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Aarti Drugs Ltd. (AARTIDRUGS) - Company History

Aarti Drugs Ltd is one of the leading pharmaceutical manufacturers in India. The company is engaged manufacturing of pharmaceuticals. ADL operates in the anti-diarrhea anti-inflammatory and anti-biotic therapeutic segments. They manufacture vitamins anti-arthritis anti-fungal antibiotics antibiotics and angiotensin converting enzyme (ACE) inhibitors in their manufacturing units located at Tarapur and Sarigam. They are having their R&D center at Tubhe Navi MumbaiThe manufacturing units of the company are GMP certified. Their products include active pharmaceutical ingredients steroids pharmaceutical intermediates and specialty chemicals such as benzene sulphonyl chloride benzene sulphonic acid/ ammonium/ sodium salt and benzene sulphonamide. They are having one subsidiary company namely Suyash Laboratories Ltd. Aarti Drugs Ltd a part of Aarti Group of Industries was incorporated in the year 1984. In the year 1993 the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95 the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also Rupal Chemical Industries a group company was amalgamated with the company.During the year 1996-97 the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01 they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03 the company expanded the production capacity of bulk drugs by 598000 kg to 17430000 kg. During the year 2003-04 the company further expanded the production capacity of bulk drugs by 588000 kg to 18018000 kg. During the year 2004-05 the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 2005-06 the company increased the production capacity of Pharmaceutical by 2325000 kg to 24020000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.During the year 2006-07 the company increased the production capacity by 570000 kg to 24590000 kg. During the next year they increased the production capacity by 399000 kg to 24989000 kg. During the year 2008-09 they further increased the production capacity of Pharmaceutical by 50000 kg to 25000000 kg.During the year 2009-10 the company carried out research and development work/ process improvement work in bulk drugs such as antihistaminic/anti-allergic anti-inflammatory and anti-diabetic. ADL has sold/exported intermediates such as Stage-I of pioglitazone and AU-% for tamsulosin. They expanded the production capacity from 25000000 kg to 25716000 kg. The company is expanding their production capacity in various products-lines to cope up the demand. They are also in the process of acquiring ISO 9002 compliance for all their units.

.